RE:RE:New Analyst Coverage: Thera "Speculative Buy"Today's action actually shows the issue with the share price, and the issue that someday we'll be happy about. And that is that a (excuse me Mr. Loe) a fairly unknown, unfollowed analyst at a firm no one's heard about can write a positive report and move the share price up 5%.
Highlights how important it is for the company to achieve those value-enhancing events so they can attract a well known analyst and a well known firm or two. Imagine what would actually happen if you had a few bigger firms turn positive -- maybe RBC will, and then add in some of the new guys --Piper Sandler, Leerink, Raymond James, Credit Suisse, Cantor Fitz, Cowen, etc.... They're not huge (except CS), but are far larger then Loe's firm and all have large clients on their lists.
Wino115 wrote: Well, well...a bag of Cheetos is on the way to good old Mr. Loe! Honestly, glad he found a job given the environment and I do have to tip my hat to him in that he was the only analyst who thought Egrifta could have an effect on a fatty liver. His numbers used to be crazy and it looks like he's had someone address his poor financial modeling and now he has a target price within the realm of some of the other analysts. Guess it leaves room for him to upgrade!
archeo753 wrote: From Today's Globe and Mail:
Calling it an “innovative HIV drug developer,” Leede Jones Gable analyst Douglas Loe initiated coverage of Theratechnologies Inc. (
) with a “speculative buy” rating.
“Theratechnologies is a diversified pharma firm, with two specialty drugs Egrifta and Trogarzo already approved and targeting niche HIV indications (HIV lipodystrophy and multidrug-resistant HIV1 infection, respectively) with substantial quarterly revenue already being generated, if a bit below our original expectations for both drugs,” he said. “Egrifta is a stabilized, fatty-acid-derivatized analog of growth hormone-releasing factor that has documented impact on reducing visceral adipose tissue deposition in HIV1-infected individuals. Trogarzo is a partnered (with Taiwan-based TaiMed Biologics (4147-TW)) anti-CD4 mAb that targets CD4-positive/HIV1-infected T-cells and mitigates HIV1 infection in patients that are no longer responsive to two or more of the small-molecule anti-retroviral drugs that are conventionally used to treat disease. Pivotal Phase III data were positive and FDA approval-enabling, and both drugs are projected to contribute positively to revenue/EBITDA throughout our forecast period.”
He set a $4 target for shares of the Montreal-based company. The average on the Street is $5.90.
=====